Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Vaccination efficacy against post-COVID-19 symptoms in Delta and Omicron waves: a prospective cohort in East Indonesia

International Journal of Public Health Science · Vol. 12 No. 1 (2023) · hlm. 32–40

DOI
10.11591/ijphs.v12i1.22470
ISSN
2620-4126, 2252-8806
Terbit
2023-03-01
Penerbit
Intelektual Pustaka Media Utama
Bahasa
eng
Lisensi
creativecommons.org/licenses/by-nc/4.0

Abstrak

The post COVID-19 symptoms affect the productivity and the quality of life among survivors. It is imperative to identify the effect of virus variants and the vaccination against post-COVID-19 symptoms. There were 242 participants from the eastern part of Indonesia diagnosed with COVID-19 during July 2021-July to 2022 were recruited online. The participants underwent data collection and semi-clinical follow-up for post-COVID-19 symptoms within 30 days after the first symptoms or from the diagnosis day using a validated clinical questionnaire and physician confirmation. Fatigue was the most reported post-COVID-19 symptom (27.7%), followed by chronic cough (21.5%) and headache (15.3%). Adjusted by confounding factors in hierarchical logistic regression, the differences in post-COVID-19 symptoms were insignificant across different variants. Regarding vaccine efficacy against three post-COVID-19 symptoms, people with two-dose vaccination significantly reported lower post-COVID-19 chronic cough (adjusted Odds Ratio 0.244 95% CI OR 0.071-0.838), but the protection against fatigue and the chronic headache was insignificant. There is an indication that vaccine efficacy may be waning along with the emerging new variants.

Jaringan kolaborasi para penulis

11 penulis · 16 tautan kepenulisan bersama · 9 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Chulalongkorn University
  • Khairun University
  • University of Indonesia
  • VinUniversity
  • Hasanuddin University
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Lafi MuniraChulalongkorn University4
Pranee LiamputtongVinUniversity2
Dewi NuryanaUniversity of Indonesia1
Nohan Arum RomadlonaUniversity of Indonesia1
Ranisa Handayani RamlanHasanuddin University1
Ferawati Rahmat WahabAfiliasi tidak diketahui1
Alvera NoviyaniChulalongkorn University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://ijphs.iaescore.com/index.php/IJPHS/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Vaccination efficacy against post-COVID-19 symptoms in Delta and Omicron waves: a prospective cohort in East Indonesia</dc:title>
	<dc:creator>Masrika, Nur Upik En</dc:creator>
	<dc:creator>Nugroho, Aryandhito Widhi</dc:creator>
	<dc:creator>Viwattanakulvanid, Pramon</dc:creator>
	<dc:creator>Herman, Bumi</dc:creator>
	<dc:description xml:lang="en-US">The post COVID-19 symptoms affect the productivity and the quality of life among survivors. It is imperative to identify the effect of virus variants and the vaccination against post-COVID-19 symptoms. There were 242 participants from the eastern part of Indonesia diagnosed with COVID-19 during July 2021-July to 2022 were recruited online. The participants underwent data collection and semi-clinical follow-up for post-COVID-19 symptoms within 30 days after the first symptoms or from the diagnosis day using a validated clinical questionnaire and physician confirmation. Fatigue was the most reported post-COVID-19 symptom (27.7%), followed by chronic cough (21.5%) and headache (15.3%). Adjusted by confounding factors in hierarchical logistic regression, the differences in post-COVID-19 symptoms were insignificant across different variants. Regarding vaccine efficacy against three post-COVID-19 symptoms, people with two-dose vaccination significantly reported lower post-COVID-19 chronic cough (adjusted Odds Ratio 0.244 95% CI OR 0.071-0.838), but the protection against fatigue and the chronic headache was insignificant. There is an indication that vaccine efficacy may be waning along with the emerging new variants.</dc:description>
	<dc:publisher xml:lang="en-US">Intelektual Pustaka Media Utama</dc:publisher>
	<dc:contributor xml:lang="en-US">Khairun University</dc:contributor>
	<dc:contributor xml:lang="en-US">Chulalongkorn University</dc:contributor>
	<dc:date>2023-03-01</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US"></dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijphs.iaescore.com/index.php/IJPHS/article/view/22470</dc:identifier>
	<dc:identifier>10.11591/ijphs.v12i1.22470</dc:identifier>
	<dc:source xml:lang="en-US">International Journal of Public Health Science (IJPHS); Vol 12, No 1: March 2023; 32-40</dc:source>
	<dc:source>2620-4126</dc:source>
	<dc:source>2252-8806</dc:source>
	<dc:source>10.11591/ijphs.v12i1</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijphs.iaescore.com/index.php/IJPHS/article/view/22470/13672</dc:relation>
	<dc:relation>https://ijphs.iaescore.com/index.php/IJPHS/article/downloadSuppFile/22470/3446</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2022 Institute of Advanced Engineering and Science</dc:rights>
	<dc:rights xml:lang="en-US">http://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>